Welcome
Support Centre
17 May 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
The PRIME Breast Cancer Trial: Postoperative Radiotherapy in Minimum-Risk Elderly
ISRCTN ISRCTN14817328
ClinicalTrials.gov identifier
Public title The PRIME Breast Cancer Trial: Postoperative Radiotherapy in Minimum-Risk Elderly
Scientific title
Acronym PRIME I
Serial number at source HTA 96/03/01
Study hypothesis To assess whether the omission of post-operative radiotherapy in women with low risk axillary node negative breast cancer (T0-2) treated by breast conservation with wide local excision and
endocrine therapy:
1. Improves quality of life
2. Is more cost-effective
Lay summary
Ethics approval Added as of 23/08/2007: Multicentre Research Ethics Committee (MREC) approval was granted by the Scotland Committee on 15 October 1998.
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Breast cancer
Participants - inclusion criteria 1. Age of 65 years or more, receiving adjuvant endocrine therapy
2. Medically suitable to attend for all treatments and follow ups
3. Histologically confirmed unilateral breast cancer of Tumour, Metastasis, Node (TMN) stages T0-2
4. No axillary node involvement on histological assessment
5. Had breast conserving surgery with complete excision on histological
assessment
6. Able and willing to give informed consent
Participants - exclusion criteria 1. Past history of pure in situ carcinoma of either breast or previous or concurrent malignancy within the past five years other than non-melanomatous skin cancer or carcinoma in situ of cervix
2. Grade III cancer with lymphatic/vascular invasion (because of higher risk of local recurrence)
Anticipated start date 01/01/1999
Anticipated end date 30/11/2005
Status of trial Completed
Patient information material
Target number of participants 255 randomised, additional 100 in parallel self-selected cohort
Interventions Please note that, as of 10 January 2008, the anticipated start and end dates of this trial have been updated from 1 September 1999 and 31 December 2003 to 1 January 1999 and 30 November 2005, respectively.

Interventions:
Patients treated by conservation surgery and adjuvant endocrine therapy will be randomised to receive or not to receive breast irradiation

See details of PRIME II trial on http://www.controlled-trials.com/ISRCTN95889329
Primary outcome measure(s) 1. Quality of life assessed by:
i. EORTC QLQ-C30 and QLQ-BR23
ii. Philadelphia Geriatric Center Morale Scale
iii. EuroQol
2. Anxiety and depression assessed by the Hospital Anxiety and
Depression Scale
3. Cost-effectiveness
Secondary outcome measure(s) 1. Loco-regional and distant recurrence rate
2. Functional status assessed by Clackmannan and Barthel scales
3. Acute and late morbidity assessed by the RTOG/EORTC SOMA scale
4. Cosmesis assessed by the Harris scale and the Van Limbergen scale
Sources of funding NIHR Health Technology Assessment Programme - HTA (UK)
Trial website http://homepages.ed.ac.uk/prime/prime.html
Publications 2007 results in http://www.ncbi.nlm.nih.gov/pubmed/17669280
Contact name Dr  Linda  Williams
  Address PRIME Administrator
Medical Statistics Unit
Medical School
Teviot Place
  City/town Edinburgh
  Zip/Postcode EH8 9AG
  Country United Kingdom
  Tel +44 (0)131 651 1631
  Fax +44 (0)131 651 1631
  Email linda.williams@ed.ac.uk
Sponsor Department of Health (UK)
  Address Quarry House
Quarry Hill
  City/town Leeds
  Zip/Postcode LS2 7UE
  Country United Kingdom
  Tel +44 (0)1132 545 843
  Email Sheila.Greener@doh.gsi.gov.uk
  Sponsor website: http://www.dh.gov.uk/en/index.htm
Date applied 19/08/2002
Last edited 21/08/2009
Date ISRCTN assigned 19/08/2002
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central